NCT02343133View on ClinicalTrials.gov

Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Hematopoietic Syndrome Due to Acute Radiation Syndrome
Interventions
BIOLOGICAL

HemaMax

DRUG

Placebo

Trial Locations (4)

32117

Covance Clinical Research Unit, Daytona Beach

47710

Covance Clinical Research Unit, Evansville

53704

Covance Clinical Research Unit, Madison

75247

Covance Clinical Research Unit, Dallas

Sponsors

Lead Sponsor

Neumedicines Inc.
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Neumedicines Inc.

INDUSTRY

NCT02343133 - Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome | Biotech Hunter | Biotech Hunter